TOKYO, Feb 2, 2023 – (JCN Newswire via SEAPRWire.com) – Mitsubishi Shipbuilding Co., Ltd., a Mitsubishi Heavy Industries (MHI) Group company based in Yokohama, has recently completed a conceptual study for an ammonia bunkering vessel capable of supplying ammonia fuel to ships. This study involved joint investigations with INPEX CORPORATION, which boasts abundant achievements and... » read more
TOKYO and CAMBRIDGE, Mass., Jan 30, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI), an anti-amyloid-beta (Abeta) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of... » read more
TOKYO and CAMBRIDGE, Mass., Jan 16, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril(1) antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s... » read more
TOKYO, Jan 11, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai has submitted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due... » read more
ROCKVILLE, MD and SHENZHEN, CHINA, Jan 5, 2023 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China... » read more
TOKYO, Dec 7, 2022 – (JCN Newswire via SEAPRWire.com) – Mitsubishi Heavy Industries, Ltd. (MHI), on December 6, signed a Memorandum of Understanding (MoU) with Guacolda Energia SpA, an independent power producer (IPP) in the Republic of Chile, to begin a feasibility study for the introduction of ammonia co-firing at a coal-fired thermal power plant... » read more
TOKYO, Nov 30, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s... » read more
TOKYO, Nov 30, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s... » read more
ROCKVILLE, MD and SHENZHEN, CHINA, Nov 17, 2022 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in... » read more
ROCKVILLE, MD and SHENZHEN, CHINA, Nov 16, 2022 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in... » read more
TOKYO, Nov 2, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received notification from Japan’s Ministry of Health, Labour, and Welfare (MHLW) that the “all-case study” specified post-marketing observational study condition required at the time of approval of antiepileptic agent Inovelon Tablets 100 mg and 200 mg (rufinamide)... » read more
TOKYO, Nov 2, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received notification that Aricept (donepezil hydrochloride), a treatment for Alzheimer’s disease and dementia with Lewy bodies that was discovered and developed in-house, has been granted Category 2* status based on the results of a reexamination of its... » read more
HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 23... » read more
TOKYO, Jul 26, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co. Ltd announced today that the company will present research from its Alzheimer’s disease (AD) pipeline, including new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild... » read more
ADELAIDE, AUS, Jul 20, 2022 – (ACN Newswire via SEAPRWire.com) – TrialWire(TM) Technology Platform, the most secure and rapid digital patient recruitment Platform for trial rescue, today announced the rollout of the proprietary SMS/Text patient contact system across all studies globally. The SMS/Text patient contact system is a world first in speed, security, and compliance... » read more
SHANGHAI, CHINA, May 13, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin, a glucokinase activator (GKA) and first-in-class investigational drug of the Company for... » read more
TOKYO and CAMBRIDGE, Mass., May 10, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational anti-amyloid beta (Abeta) protofibril antibody... » read more
TOKYO, Apr 19, 2022 – (JCN Newswire via SEAPRWire.com) – ENEOS Corporation and Mitsubishi Corporation have agreed to undertake a joint feasibility study aimed at commercializing Sustainable Aviation Fuel (SAF) and other next-generation fuels in Japan. This study aims to build a supply chain for SAF, which requires cross-industrial collaboration, by leveraging both companies’ respective... » read more
CAMBRIDGE, Mass., and TOKYO, Mar 22, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer’s disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at... » read more